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Abstract
Objective—To estimate risk of colorectal cancer (CRC) for first-degree relatives of CRC cases 
based on CRC molecular subtypes and tumor pathology features.
Design—We studied a cohort of 33,496 first-degree relatives of 4,853 incident invasive CRC 
cases (probands) who were recruited to the Colon Cancer Family Registry through population 
cancer registries in the US, Canada, and Australia. We categorized the first-degree relatives into 
four groups: 28,156 of 4,095 mismatch repair (MMR)-proficient probands, 2,302 of 301 MMR-
deficient non-Lynch syndrome probands, 1,799 of 271 suspected Lynch syndrome probands, and 
1,239 of 186 Lynch syndrome probands. We compared CRC risk for first-degree relatives 
stratified by the absence or presence of specific tumor molecular pathology features in probands 
across each of these four groups and for all groups combined.
Results—Compared with first-degree relatives of MMR-proficient CRC cases, a higher risk of 
CRC was estimated for first-degree relatives of CRC cases with suspected Lynch syndrome 
(hazard ratio [HR] 2.06, 95% confidence interval [CI] 1.59-2.67), and with Lynch syndrome (HR 
5.37, 95% CI 4.16-6.94), but not with MMR-deficient non-Lynch syndrome (HR 1.04, 95% CI 
0.82-1.31). A greater risk of CRC was estimated for first-degree relatives if CRC cases were 
diagnosed before age 50 years, had proximal colon cancer or if their tumors had any of the 
following: expanding tumor margin, peritumoral lymphocytes, tumor-infiltrating lymphocytes, or 
synchronous CRC.
Conclusion—Molecular pathology features are potentially useful to refine screening 
recommendations for first-degree relatives of CRC cases, and to identify which cases are more 
likely to be caused by genetic or other familial factors.
Keywords
colorectal cancer; molecular pathology, mismatch repair deficiency, relatives; risk prediction; 
Lynch syndrome, suspected Lynch syndrome
INTRODUCTION
Having a family history of colorectal cancer (CRC) is a well-established risk factor for the 
disease; people with one first-degree relative (parent, offspring, sibling) with CRC are, on 
average, twice as likely to be diagnosed with CRC than those without a family history.(1, 2) 
This has clinical implications for prevention as more intensive screening can be targeted to 
those who have a relative with CRC; many guidelines for CRC screening reflect this 
approach.(3-6) In addition, CRC diagnosed in a setting of a family history is more likely to 
be due to an inherited mutation and, when identified through genetic screening, has 
significant and quantifiable risks for CRC and other cancers.(7-9) However, there is 
substantial variation around this average risk of family history.(10) For example, the 
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younger the age at diagnosis of the affected relative and the more closely related the affected 
relative, the greater the risk.(11)
As for breast cancer, recent analyses of population-based family studies have shown that, at 
least and perhaps more so for cancers diagnosed before the age of 40 years, tumor 
morphology can be used to further sub-categorise familial risks. For example, trabecular 
growth pattern and high mitotic index are strong predictors for having a germline mutation 
in BRCA1,(12) and hence predict risk for first-degree relatives. After excluding known 
BRCA1 and BRCA2 mutation carriers, absence of extensive sclerosis, circumscribed growth, 
extensive intraductal carcinoma, and a lobular growth pattern of breast cancers were 
independent predictors associated with a two- to three-fold increased risk of breast cancer 
for first-degree relatives.(13) The first-degree relatives of the one-third of early-onset cases 
who had none of these morphology features showed no evidence for an increased (familial) 
risk of breast cancer.
For CRC, it is well established that tumor molecular features can predict germline mutation 
status with greater sensitivity and specificity and in a more cost-effective way than using 
family history alone, particularly in early-onset disease.(14) Tumor-infiltrating lymphocytes, 
proximal colonic location, mucinous histology, poor differentiation and Crohn’s-like 
reaction are now well-recognized pathology predictors for mismatch repair (MMR)-
deficiency resulting from a germline mutation in one of the MMR genes.(15, 16) In this 
study, we estimated CRC risk for first-degree relatives of CRC cases based on tumor 
molecular subtypes and tumor pathology features.
MATERIALS AND METHODS
Study Sample
We studied a cohort of the first-degree relatives of people with incident invasive CRC 
(probands) recruited by the Colon Cancer Family Registry between 1997 and 2007 through 
state or regional population cancer registries in the USA (Washington, California, Arizona, 
Minnesota, Colorado, New Hampshire, North Carolina, and Hawaii), Australia (Victoria) 
and Canada (Ontario). Study designs and recruitment for the Colon Cancer Family Registry 
can be found at http://coloncfr.org/ and have been previously published in detail.(17) 
Written informed consent was obtained from all study participants, and the study protocol 
was approved by the institutional research ethics review board at each study center.
Data Collection
Information on demographics, personal characteristics, personal and family history of 
cancer, cancer-screening history, and history of polyps, polypectomy, and other surgeries 
was obtained by questionnaires from all probands and participating relatives. Participants 
were followed up approximately every 5 years after baseline to update information across all 
the study centers. The present study was based on all available baseline and follow-up data 
until 2012. Reported cancer diagnoses and age at diagnosis were confirmed, where possible, 
using pathology reports, medical records, cancer registry reports, and death certificates. The 
tumor anatomic location and histology were coded and stored using International 
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Classification of Diseases for Oncology, third edition (ICD-O-3).(18) Blood samples and 
permission to access tumor tissue were requested from all participants.
Colorectal Cancer Tumor Pathology Review
Probands’ CRCs were reviewed by pathologists from each study center of the Colon Cancer 
Family Registry and assessed for the following features: histologic type (adenocarcinoma, 
mucinous, signet ring cell), histologic grade (low or high grade), tumor margin (expanding 
or infiltrative), and peritumoral lymphocytes, Crohn’s-like reaction, tumor-infiltrating 
lymphocytes, venous invasion, and synchronous CRC (present or absent). Tumors were 
classified as mucinous carcinoma or signet-ring-cell carcinoma if at least 50% of the tumor 
demonstrated the specific morphology. Low-grade was defined as adenocarcinoma with 
≥50% gland formation and high-grade as adenocarcinoma with <50% gland formation. 
Tumor margin describes the advanced edge of the tumor into the bowel wall and was 
categorized as expanding margin for well-circumscribed edge pushing into the deep portion 
of the wall and infiltrative margin for widespread dissection of the bowel wall by the cancer 
cells.(19) The presence of peritumoral lymphocytes was based on the finding of a cap of 
lymphocytes at the deepest part of the invasive tumor front.(20) Crohn’s-like reaction was 
recorded as present for tumors demonstrating at least 4 nodular lymphoid aggregates within 
a single x4 field, deep to the advancing edge of the tumor.(21) Tumor-infiltrating 
lymphocytes were regarded as present when ≥5 intratumoral lymphocytes were identified 
within a single x40 field of a hematoxylin and eosin-stained section.(16) Colon cancer was 
defined as any diagnosis of cancer in the proximal colon (caecum to transverse colon; ICD-
O-3 codes C18.0, C18.2–C18.4), distal colon (splenic flexure to sigmoid colon; C18.5–
C18.7), or an unspecified location of the colon (C18.8, C18.9 and C26.0). Rectal cancer was 
defined as any diagnosis of cancer in the rectosigmoid junction (C19.9) and rectum (C20.9 
and C21.8).
Molecular Characterization
Mismatch repair status—Probands’ CRCs were characterized for MMR-deficiency by 
microsatellite instability (MSI) using a ten-marker panel and/or by immunohistochemistry 
(IHC) for the four MMR proteins.(22) Tumors were classified as MMR-deficient if they 
were MSI-high (≥30% or more of the markers show instability) and/or showed loss of 
expression of one or more of the MMR proteins by IHC; and MMR-proficient if they were 
microsatellite stable (no unstable markers) or MSI-low (<30% unstable markers) and/or 
showed normal expression of all four MMR proteins by IHC. Of the 4843 proband CRCs 
with a MMR IHC or MSI result, 3325 (68.7%) had both tests performed, 1508 (31.1%) had 
MMR IHC only and 10 (0.2%) had MSI only (Supplementary table 1). Of the 3325 proband 
CRCs that had both tests performed, 3202 were concordant between MSI and MMR IHC 
(96.3%, 95% confidence intervals (CIs) 95.6–96.9%). Probands with a MMR-deficient CRC 
underwent germline mutation testing (Sanger sequencing and MLPA) as previously 
described.(17, 23-25)
Molecular testing—A fluorescent allele-specific PCR assay was used to detect the 
somatic T>A mutation at nucleotide 1799 in exon 15 of the BRAF gene (BRAF V600E) as 
has been previously described.(26, 27) Methylation of the MLH1 gene promoter was 
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measured in all MSI-high and MSI-low cases with sufficient tumor DNA and a random 
sample of microsatellite-stable cases. MLH1 methylation was measured using the 
MethyLight MLH1-M2Methylight reaction using an ALU control reaction to normalize for 
bisulfite-converted input DNA,(28) with the modifications described in Poynter et al.(29) 
We classified samples with a proportion of methylated reference (PMR) greater than or 
equal to 10 as positive for MLH1 methylation. An ALU control reaction cycle threshold 
[C(t)] value of <25 was used to retain the largest sample size possible for the analysis while 
minimizing the potential for false negatives.
Classification
We categorized the probands into four groups:
• “MMR-proficient”: probands with a mismatch repair (MMR)-proficient CRC;
• “MMR-deficient non-Lynch syndrome”: probands with a CRC that had loss of 
MLH1 and PMS2 protein expression with evidence of MLH1 methylation and/or 
had the BRAF V600E mutation;
• “Suspected Lynch syndrome”: probands with a CRC that had MLH1/PMS2 loss 
with no evidence of MLH1 methylation and/or BRAF V600E mutation or had 
MSH2/MSH6 loss or solitary loss of PMS2 or MSH6 or were MSI-H, for which no 
MMR germline mutation had been identified; and
• “Lynch syndrome”: probands known to carry a pathogenic MMR germline 
mutation.
Statistical Analysis
Observation time for each member of the cohort (a first-degree relative of a CRC-proband) 
started at birth and ended at: first diagnosis of invasive cancer; first polypectomy; last 
contact; or death, whichever occurred earliest. Of the 35,567 first-degree relatives, 
unaffected relatives with no information on age were censored at birth i.e., excluded from 
analysis (n=2071; 6%) and the remaining 33,496 entered into the analysis. For cancer-
affected relatives with missing age at diagnosis (n=120; 0.4%), age at diagnosis was 
assumed to be one year prior to the last known age (n=102) or, if last known age was not 
available, the median age at diagnosis of the specific cancer in the general population 
(n=18). The sex-specific median age for each cancer was obtained from the SEER Cancer 
Statistics Review (1975– 2000).(30)
We estimated the standardized incidence ratio (SIR) of CRC for the first-degree relatives of 
CRC cases compared with the general population as a function of measured covariates by 
using the data on first-degree relatives of case-probands. Each SIR was calculated by 
dividing the observed number of CRCs first-degree relatives by the number expected based 
on the age-, sex- and country-specific incidence in the general population.(31) The Jackknife 
method was used to estimate 95% CIs to adjust for correlation of risk between relatives from 
the same family.(32)
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In this study, exposure is the tumor pathology features of colorectal cancer of the proband 
and outcome is the incidence of CRC in the first-degree relatives. We estimated CRC hazard 
ratios (HRs) for first-degree relatives of CRC cases depending on the absence or presence of 
specific tumor pathology features. The HRs and robust estimates of corresponding 95% CIs 
were calculated from Cox proportional hazard regression models by taking into account 
clustering by family membership to allow for correlation of risk between relatives from the 
same family.(33) To investigate independent associations of the tumor pathology features 
with familial risk, we fitted variables that showed a nominally statistically significant 
association in the univariable analyses into a multivariable model. We estimated CRC risk 
for first-degree relatives associated with a total number of proband’s features that were 
shown to be statistically significant in the multivariable model, as a categorical (≥3 vs <3) as 
well as continuous (per feature) factor.
To account for the missing values that occurred for some pathology features, we devised a 
multiple imputation model based on previous recommendations of Van Buuren et al.(34) 
and Ali et al.(35) The missing data were assumed to be ‘missing at random’ so that the 
reason for missingness can be explained by the observed data.(36) The model included all 
predictor variables, the outcome variable (diagnosis of CRC) and additional variables that 
we considered may increase the plausibility of the missing at random assumption in order to 
improve the imputation process. While some researchers claim that as few as 3–5 imputed 
datasets is sufficient for imputation,(37) we chose 10 sets based on recommendations that 
the number of sets should approximate the percentage of subjects with some missing data.
(38) Location of CRC was imputed using polytomous logistic regression while the other 
pathology features were imputed using logistic regression. Missing values were sampled and 
replaced with a set of plausible values randomly drawn from their predicted distribution 
based on the other observed variables, thus creating 10 completed datasets. Cox proportional 
hazard regression models were run separately for each imputed data set and estimates of the 
predictor variables were combined using the programmes written by Carlin et al.(39) As a 
sensitivity analysis, we also compared the estimates of association using the imputed 
missing data with the estimates from a complete case analysis.
Some centers of the Colon Cancer Family Registry used stratified sampling based on family 
history for recruitment and we did take this into account when combining and analyzing the 
data. To adjust for this stratified sampling, we gave each relative a probability weight equal 
to the reciprocal of the family sampling fraction of their proband used by each study center.
(17) All statistical tests were two-sided and p<0.05 was regarded as nominally statistically 
significant. All statistical analyses were performed using Stata 12.1.(40)
RESULTS
Of the 4,853 probands with an invasive CRC from the population-based resources of the 
Colon Cancer Family Registry, 4,095 (84%) were MMR-proficient; 301 (6%) were MMR-
deficient non-Lynch syndrome; 271 (6%) were suspected Lynch syndrome (104 MLH1/
PMS2 loss, 45 MSH2/MSH6 loss, 17 PMS2 loss, 27 MSH6 loss, and 78 MSI-high), and 186 
(4%) were Lynch syndrome with confirmed pathogenic mutations in MMR gene mutations 
(59 MLH1, 70 MSH2, 25 MSH6, 30 PMS2, 2 EPCAM). The probands were diagnosed with a 
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CRC at a mean age of 54.2 (standard deviation [SD] 11.6) years, with approximately one-
third of tumors diagnosed in each of the proximal colon, distal colon, and rectum (Table 1). 
Compared with MMR-proficient probands, the mean age at diagnosis of CRC was 10.3 
(95%CI 9.02–11.6) years older for MMR-deficient non-Lynch syndrome probands, 5.28 
(95%CI 3.95–6.61) years younger for suspected Lynch syndrome probands, and 9.33 
(95%CI 7.74– 10.9) years younger for Lynch syndrome probands (Supplementary Table 2).
We identified 33,496 first-degree relatives of the participating probands: 28,156 (84%) 
relatives of MMR-proficient probands; 2,302 (7%) of MMR-deficient non-Lynch syndrome 
probands; 1,799 (5%) of suspected Lynch syndrome probands, and 1,239 (4%) of Lynch 
syndrome probands (Table 2). Of all first-degree relatives, 1,404 (4%) were diagnosed with 
a CRC at a mean age of 62.1 (SD 14.1) years. Compared with first-degree relatives of 
MMR-proficient probands, mean age at diagnosis of CRC was 3.10 (95%CI 0.57–5.63) 
years older for first-degree relatives of MMR-deficient non-Lynch syndrome probands, 6.01 
(95%CI 3.54–8.47) years younger for first-degree relatives of suspected Lynch syndrome 
probands, and 14.8 (95%CI 12.5–17.0) years younger for first-degree relatives of Lynch 
syndrome probands (Supplementary Table 2). Verification was sought for all reported CRCs 
in the relatives. Of the 1404 CRCs reported in the first-degree relatives, 605 (43%) had been 
verified by pathology reviews, medical records, death certificates or cancer registries 
(Supplementary Table 3). For cancers that we could not obtain verification, we did not 
solely rely on the proband to report family history of cancer. Rather, we interviewed 
multiple family members to ascertain all diagnoses of cancer in family. For apparently 
conflicting reports within the family, we gave priority to the report provided by the closest 
family member.
Using all the data, we observed 1,404 CRCs in the 33,496 first-degree relatives of CRC 
cases over the 1,792,526 person-years. We estimated that first-degree relatives of CRC cases 
had an approximately 2-fold higher risk of CRC compared with the general population (SIR 
1.79, 95%CI 1.66–1.94). Compared with first-degree relatives of MMR-proficient CRC 
cases, a higher risk of CRC was estimated for first-degree relatives of suspected Lynch 
syndrome CRC cases (HR 2.06, 95%CI 1.59–2.67), and for first-degree relatives of Lynch 
syndrome CRC cases (HR 5.37, 95%CI 4.16–6.94), but not for relatives of MMR-deficient 
non-Lynch syndrome CRC cases (HR 1.04, 95%CI 0.82–1.31) (Table 3).
A higher risk of CRC was estimated for first-degree relatives if the CRC case’s tumor had: 
diagnosis before age 50 years (HR 1.64, 95%CI 1.43–1.88); a proximal colonic location (HR 
1.33, 95%CI 1.16–1.53); an expanding tumor margin (HR 1.66, 95%CI 1.35–2.05); 
peritumoral lymphocytes (HR 1.26, 95%CI 1.06–1.49); tumor-infiltrating lymphocytes (HR 
1.33, 95%CI 1.15–1.55); and a synchronous tumor (HR 1.69, 95%CI 1.23–2.32) (Table 4). 
There was marginal evidence that presence of Crohn’s-like reaction in CRC case was 
associated with a higher CRC risk for first-degree relatives (HR 1.17, 95%CI 0.99–1.49). 
There was no evidence that CRC risks for first-degree relatives depend on the CRC case’s 
sex (p=0.42), tumor histologic subtype (p=0.68), grade (p=0.72), and venous invasion 
(p=0.91) (See detail in Supplementary Table 4).
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We therefore fitted proband’s age at diagnosis, tumor location, tumor margin, peritumoral 
lymphocytes, tumor-infiltrating lymphocytes and synchronous CRC in the multivariable 
model (Table 5). When combined all groups, we found that the CRC case’s age at diagnosis 
<50 years (HR 1.61, 95%CI 1.40–1.87), tumor proximal colonic location (HR 1.29, 95%CI 
1.12–1.49), expanding tumor margin (HR 1.48, 95%CI 1.19–1.83), presence of peritumoral 
lymphocytes (HR 1.21, 95%CI 1.01– 1.44), presence of tumor-infiltrating lymphocytes (HR 
1.21, 95%CI 1.03–1.43), and presence of synchronous CRC (HR 1.61, 95%CI 1.19–2.18) 
were all independently associated with an increased CRC risk for first-degree relatives. 
When we stratified by MMR-deficiency status of the CRC case, we estimated that a higher 
risk of CRC for first-degree relatives was associated with: age at diagnosis <50 years 
(p=0.008) and an expanding tumor margin (p<0.001) when the CRC case was MMR-
proficient; age at diagnosis <50 years (p=0.006) and presence of synchronous CRC 
(p=0.004) when the CRC case was MMR-deficient non-Lynch syndrome; and age at 
diagnosis <50 years (p=0.001) and presence of peritumoral lymphocytes (p<0.001) when the 
CRC case was Lynch syndrome (Table 5).
When we combined the proband’s age at diagnosis and tumor pathology features that were 
independently associated with CRC risk for first-degree relatives, we estimated that there 
was an approximately two-fold increased risk of CRC for first-degree relatives (HR 1.91, 
95%CI 1.65–2.22) if probands had three or more of the following six features: age at 
diagnosis <50 years, tumor’s proximal colonic location, presence of expanding tumor 
margin, peritumoral lymphocytes, tumor-infiltrating lymphocytes and synchronous CRC. 
When we stratified by MMR-deficiency status of the CRC case, the approximate two-fold 
increase in risk was still present for first-degree relatives of CRC cases with three or more 
features compared with first-degree relatives of CRC cases with less than three features in 
each group (Table 6).
When we fitted these six features as a continuous factor, we estimated the HR per feature of 
the CRC case to be 1.33 (95%CI 1.26–1.42) for first-degree relatives when combined all 
groups, 1.21 (95%CI 1.13–1.30) for first-degree relatives of MMR-proficient CRC cases, 
1.54 (95%CI 1.23–1.92) for first-degree relatives of MMR-deficient non-Lynch syndrome 
CRC cases, 1.28 (95%CI 1.06–1.55) for first-degree relatives of suspected Lynch syndrome 
CRC cases, and 1.33 (95%CI 1.11– 1.58) for first-degree relatives of Lynch syndrome CRC 
cases.
In a complete case analysis without any missing data, we found that use of the imputed 
missing data had no considerable effect on estimates of association (details not shown). We 
also estimated CRC risk for first-degree relatives by fitting the specific tumor location of the 
proband as an ordinal (continuous) variable in the model. We found a hazard ratio of 1.05 
(95%CI 1.02–1.07) showing that the more proximally located CRC of the proband is 
associated with the higher risk of CRC for first-degree relatives when combined all groups 
(Supplementary Table 5). When we investigated the association between BRAF V600E 
mutation of proband’s CRC tumor and CRC risk for first-degree relatives, we found no 
evidence of association even after stratification by MMR status (Supplementary Table 6).
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Using a large family cohort study, we estimated that first-degree relatives of suspected 
Lynch syndrome CRC cases had a higher risk of CRC compared with first-degree relatives 
of MMR-proficient CRC cases, and a lower risk of CRC compared with first-degree 
relatives of Lynch syndrome CRC cases. We found that first-degree relatives had a higher 
risk of CRC if the CRC case was diagnosed <50 years, had proximal colon cancer, an 
expanding tumor margin, peritumoral lymphocytes, tumor-infiltrating lymphocytes, or a 
synchronous CRC. These CRC features could be useful in identifying the first-degree 
relatives of CRC cases who are at increased CRC risk, even within a specific molecular 
subtype of CRC.
The clinical management of CRC cases with suspected but genetically unproven to have 
Lynch syndrome (i.e. MMR-deficient, no MMR germline mutation, and not MHL1-
methylated or BRAF-mutated), and of their relatives, can be particularly challenging as it is 
not possible to distinguish which if any relatives are at increased risk because they carry a 
mutation in an MMR gene. Little is known about the cancer risks for members of these 
families and therefore screening and treatment guidelines are not well defined. The average 
age at CRC diagnosis for first-degree relatives of CRC cases with suspected Lynch 
syndrome was between that for first-degree relatives of MMR-proficient cases and that for 
first-degree relatives of confirmed Lynch syndrome cases (58 vs 49 and 64 years, 
respectively). We estimated that CRC risk for first-degree relatives of suspected Lynch 
syndrome CRC cases was between that for first-degree relatives of MMR-proficient cases 
and that for first-degree relatives of confirmed Lynch syndrome cases, and this is consistent 
with the observation by Rodriguez-Soler et al.(41)
It is possible that a proportion of these suspected Lynch syndrome CRC cases might be due 
to the existence of complex or cryptic mutations in MMR genes that are not readily 
identified by current Sanger sequencing and MLPA techniques.(42-44) It could also be 
argued that the suspected Lynch syndrome CRC cases carrying undetected mutations have 
associated with them a more moderate CRC penetrance compared with that for the exonic 
and splice site mutations that are more readily detected.(45) With the increasing use of next 
generation sequencing in clinical diagnostics, further investigation of more complex and 
cryptic mutational mechanisms will be possible. This will be accompanied by an increasing 
need to assess the pathogenicity of variants of uncertain clinical significance (VUS) in the 
MMR genes and quantify the risk of CRC for carriers of VUS and their relatives, and build 
upon the significant progress achieved to date.(46, 47) Alternatively, a proportion of 
suspected Lynch syndrome cases have been shown to result from somatic inactivation 
within the tumor through biallelic mutations.(48, 49) Though an intermediate screening 
recommendation has been recommended for suspected Lynch syndrome families,(41) 
optimal screening strategies are yet to be defined given this group is likely to be 
heterogeneous with regards to family history and to the mechanism of MMR inactivation.
First-degree relatives of CRC cases with confirmed Lynch syndrome have a greater CRC 
risk than first-degree relatives of MMR-proficient CRC cases. Current screening 
recommendations for untested first-degree relatives of Lynch syndrome CRC cases is 
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typically annual colonoscopy starting at age 20-25 years, or 10 years younger than the 
youngest diagnosed CRC in the family, whichever is earliest.(50) Our finding that the 
average age at CRC diagnosis for first-degree relatives of Lynch syndrome cases is 
approximately 15 years earlier than for first-degree relatives of MMR-proficient cases 
supports the rationale for starting CRC screening at an earlier age in first-degree relatives of 
Lynch syndrome cases until they have been genetically tested and shown not to be MMR 
gene mutation carriers. Similarly, our finding that younger age at diagnosis of CRC for 
Lynch syndrome cases is a risk factor for CRC in their first-degree relatives supports the 
rationale for varying the recommendations for age of starting CRC screening in first-degree 
relatives based on the age of the youngest CRC in the family.
We estimated that first-degree relatives of MMR-proficient CRC cases and MMR-deficient 
non-Lynch syndrome CRC cases had an approximately 1.6-fold higher risk of CRC 
compared with the general population. Current CRC screening recommendations for first-
degree relatives of CRC cases vary but in general the recommendation is to start screening 
earlier (at age 40 rather than age 50 for those without a family history of CRC) and to use 
colonoscopy if the CRC occurs in a relative before the age of 60 years. Our data that a 
younger age of the proband’s CRC was associated with an increased CRC risk for first-
degree relatives of both the MMR-proficient and MMR-deficient non-Lynch syndrome CRC 
cases, is consistent with this type of age-dependent screening recommendations.
We found that first-degree relatives of MMR-deficient CRC cases as a result of MLH1 
methylation were at no greater risk of CRC compared with first-degree relatives of MMR-
proficient CRC cases. However, we estimated that CRC risk for first-degree relatives of 
MMR-deficient non-Lynch syndrome cases is about 4.5-fold higher when the case’s CRC 
was diagnosed before age 50 years and about 2-fold greater when the case had a 
synchronous CRC. It is possible that this increased CRC risk may be explained by shared 
lifestyle and environmental factors within families, such as smoking, which has been 
reported to be associated with MMR-deficient and BRAF-mutated CRC.(51) These features 
are also comparable with familial serrated neoplasia (Jass syndrome)(52) which has been 
linked to 2q33,(53) and characterised by early age at diagnosis, multiplicity of lesions, 
presence of BRAF V600E-mutated and MLH1-methylated MSI-H CRCs.(54)
We found no evidence of an association between BRAF V600E mutation status of proband’s 
CRC tumor and an increased risk of CRC for their first-degree relatives, even after 
stratification by MMR status. A subset of this data has been previously reported highlighting 
an inverse association between BRAF-mutated CRC and family history of CRC.(27) In 
contrast, three other studies support an association between a family history of CRC and an 
increased risk of the BRAF-mutated CRC.(55-57) One potential explanation for the 
discrepancy in findings between this study and the previous reports might be the difference 
in the mean age at diagnosis of the CRC cases.
In this study, the molecular features analyzed were those commonly utilized for the 
identification of Lynch syndrome. Additional molecular features may provide greater 
insights for CRC risk prediction for relatives. Two studies recently reported that a family 
history of CRC is associated with a high risk of MMR-proficient CRC with low-levels of 
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tumor LINE-1 methylation (LINE-1 hypomethylation).(58, 59) Furthermore, the recent 
comprehensive characterization of CRCs from the The Cancer Genome Atlas project has 
identified many key genetic and epigenetic mutations in CRC.(60) Although these tumor 
molecular features were beyond the scope of this study they require further investigation in 
large resources for their effectiveness in CRC risk prediction for relatives.
Currently anatomic and pathology features of CRCs are not used to guide CRC screening 
intensity or to estimate CRC risk for relatives. We found that proximal colonic location, 
synchronous CRCs, expanding tumor margin and inflammatory infiltrate assessed by the 
presence of peritumoral lymphocytes, and tumor infiltrating lymphocytes in the proband’s 
tumor are associated with an increased CRC risk for first-degree relatives. Many of these 
pathology features are strongly associated with MMR-deficiency secondary to Lynch 
syndrome or caused by somatic alterations in MMR genes.(15, 16) The mechanism 
accounting for the prominent inflammation in MMR-deficient CRC (peritumoral 
lymphocytes, tumor infiltrating lymphocytes and Crohn’s-like reaction) is unclear and may 
be related to the host response to tumor cells demonstrating an altered phenotype. 
Interestingly, some of these pathology features were also found to be associated with a 
higher CRC risk for first-degree relatives of MMR-proficient CRC. This may be due to 
undetected MMR gene mutations within MMR-proficient CRC cases (61), or alternatively 
molecular alterations other than MMR-deficiency may trigger a similar immunological 
reaction in the tumor environment.
When analyzed for each of the molecular subtypes of CRCs, there was a complex 
relationship of these pathologic features to CRC risk for first-degree relatives. In an effort to 
simplify the pathology analysis, we investigated the role of all of the pathology factors that 
were related to CRC risk for first-degree relatives and found that having three or more 
features in CRC cases was associated with an increased CRC risk for first-degree relatives in 
the entire group as well as all of the molecular subtypes. When we considered the specific 
colorectal tumor location of the proband, we found an increased risk of CRC for first-degree 
relatives with a more proximal location of CRC in the proband. Further larger studies will be 
required to gain enough power to investigate the effect of specific colorectal tumor location 
in each specific molecular subtype of CRC. This site-specific study may be more 
informative to understand site-specific tumor molecular pathology feature differences 
beyond the simple proximal-distal divide.(62) Future studies with computer-assisted 
morphology analysis may identify new pathology features associated with an increased 
cancer risk for relatives.(63)
This is the first study to investigate the association of CRC tumor molecular pathology 
features with CRC risk for relatives. We used a large population-based cohort of first-degree 
relatives of incident CRC cases, and therefore inference can be readily made, at least to the 
populations from which these families were sampled, if not more generally. Family history 
of cancer was collected in a systematic manner across the Colon Cancer Family Registry. 
Our application of weights to each relative depending on the different sampling strategies 
used by some centers of the Colon Cancer Family Registry would minimize any selection 
bias due to sampling based on family history.
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For CRC cases with suspected Lynch syndrome and confirmed Lynch syndrome, we 
estimated risk for all first-degree relatives, even though, on average only half will carry a 
mutation in an MMR gene. Therefore, if suspected Lynch syndrome is due to an autosomal 
dominantly inherited syndrome the associations for both these groups are an average over 
carrier and non-carrier relatives. Our study families were predominantly Caucasians and we 
therefore cannot infer that these results apply to other ethnic groups. Further, we did not 
report risks of cancers other than CRC for relatives given we emphasized only on 
associations between CRC tumor molecular pathology features and risk of CRC for their 
first-degree relatives in this study. 57% of colorectal cancer diagnosis in the first-degree 
relatives were based on the proband’s or relative’s self-report which, if a proportion are false 
positive, may lead to an underestimation of the true associations. However, the specificity of 
self-reported cancer diagnoses is generally more than 98% suggesting that there are few 
false positives in such data (64). It is possible that people who are likely to have a genetic 
predisposition give a more complete family history of cancer compared with those who are 
not. If this is the case, there will be more complete cancer diagnosis data reported in Lynch 
syndrome or suspected Lynch syndrome families rather than non-Lynch syndrome families.
In conclusion, findings from this study provide evidence that molecular and pathology 
characterization of CRCs can both help define the CRC risk for first-degree relatives, and 
therefore may be useful to refine screening recommendations for first-degree relatives of 
CRC cases and to identify which cases are more likely to be caused by genetic or other 
familial factors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What is already known about this subject?
• Family history of colorectal cancer (CRC) is a well-established risk factor for 
the disease, but even for specific family histories there is a wide variation in 
CRC risk limiting the effectiveness of CRC screening based on family history 
alone.
• We hypothesized that molecular and pathology features of a colorectal cancer 
may be useful to estimate CRC risk for their relatives.
What are the new findings?
• Compared with first-degree relatives of MMR-proficient CRC cases, a higher 
risk of CRC was estimated for first-degree relatives of CRC cases with 
suspected Lynch syndrome (hazard ratio [HR] 2.06, 95% confidence interval 
[CI] 1.59-2.67), and with Lynch syndrome (HR 5.37, 95% CI 4.16-6.94), but not 
with MMR-deficient non-Lynch syndrome (HR 1.04, 95% CI 0.82-1.31).
• A greater risk of CRC was estimated for first-degree relatives if CRC cases were 
diagnosed before age 50 years, had proximal colon cancer or if their tumors had 
any of the following: expanding tumor margin, peritumoral lymphocytes, tumor-
infiltrating lymphocytes, or synchronous CRC.
How might it impact on clinical practice in the foreseeable future?
• Molecular and pathology characterization of CRCs can help define the risk of 
CRC for first-degree relatives, and therefore may be useful to refine screening 
recommendations for first-degree relatives of CRC cases and also to identify 
which cases are more likely to be caused by genetic or other familial factors.
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Table 1




















female 2,368 (49) 1,945 (48) 221 (73) 118 (44) 83 (45)
male 2,485 (51) 2,149 (52) 80 (27) 153 (56) 103 (55)
Country
Canada 1,610 (33) 1,366 (33) 99 (33) 79 (29) 66 (35)
USA 2,439 (50) 2,015 (49) 192 (64) 144 (53) 88 (47)
Australia 804 (17) 714 (17) 10 (3) 48 (18) 32 (17)
Age at diagnosis (years)
mean (SD) 54.2 (11.6) 54.2 (11.2) 64.5 (8.31) 48.8 (12.3) 45.0 (11.3)
median (range) 53 (18-75) 53 (18-75) 66 (22-74) 47 (18-74) 45 (18-74)
Location
rectum 1,647 (34) 1,568 (39) 10 (3) 42 (16) 27 (15)
distal colon 1,488 (31) 1,352 (33) 30 (10) 65 (24) 41 (22)
proximal colon 1,656 (35) 1,124 (28) 256 (86) 159 (60) 117 (63)
missing 62 51 5 5 1
Histologic
type




631 (14) 441 (11) 80 (29) 67 (26) 43 (27)
missing 294 231 21 17 25
Histologic grade
low grade 3,455 (81) 3,042 (83) 152 (60) 146 (67) 115 (78)
high grade 817 (19) 609 (17) 102 (40) 73 (33) 33 (22)
missing 581 444 47 52 38
Tumor margin
infiltrating 1,046 (62) 926 (64) 53 (73) 38 (43) 29 (38)
expanding 646 (38) 527 (36) 20 (27) 51 (57) 48 (62)
missing 3,161 2,642 228 182 109
Peritumoral lymphocytes
absent 1,195 (64) 1,056 (66) 41 (56) 55 (48) 43 (48)
present 675 (36) 537 (34) 32 (44) 59 (52) 47 (52)









































missing 2,983 2,502 228 157 96
Crohn’s-like reaction
absent 1,358 (73) 1,228 (77) 32 (44) 57 (50) 41 (46)
present 510 (27) 363 (23) 41 (56) 57 (50) 49 (54)
missing 2,985 2,504 228 157 96
Tumor-infiltrating lymphocytes
absent 1,414 (74) 1,339 (82) 16 (22) 38 (33) 21 (23)
present 495 (26) 289 (18) 57 (78) 77 (67) 72 (77)
missing 2,944 2,467 228 156 93
Venous invasion
absent 2,749 (83) 2,330 (83) 157 (82) 157 (87) 105 (88)
present 544 (17) 472 (17) 34 (18) 24 (13) 14 (12)
missing 1,560 1,293 110 90 67
Synchronous tumor
absent 4,137 (97) 3,520 (97) 248 (93) 229 (97) 140 (93)
present 130 (3) 93 (3) 19 (7) 8 (3) 10 (7)
missing 586 482 34 34 36
SD=standard deviation; MMR=mismatch repair
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Table 2




















female 16,770 (50) 14,088 (49) 1,139 (49) 910 (51) 633 (51)
male 16,726 (50) 14,068 (51) 1,163 (51) 889 (49) 606 (49)
Country
Canada 11,645 (35) 9,842 (35) 807 (35) 562 (31) 434 (35)
USA 16,562 (50) 13,580 (48) 1,435 (62) 959 (53) 588 (47)
Australia 5,289 (16) 4,734 (17) 60 (3) 278 (15) 217 (18)
Colorectal cancer
absent 32,092 (96) 27,145 (96) 2,184 (95) 1,675 (93) 1,088 (88)
present 1,404 (4) 1,011 (4) 118 (5) 124 (7) 151 (12)
Age at diagnosis* (years)
mean (SD) 62.1 (14.1) 63.9 (13.1) 67.1 (12.8) 57.9 (14.8) 49.1 (13.1)
median (range) 64 (17-90) 65 (17-90) 68 (33-90) 58 (22-90) 46 (24-84)
Last known age^ (years)
mean (SD) 53.1 (19.8) 53.1 (19.7) 58.5 (18.2) 51.0 (19.7) 46.0 (20.1)
median (range) 53 (1-90) 53 (1-90) 58 (1-90) 51 (1-90) 46 (1-90)
*
Age at diagnosis at colorectal cancer for colorectal cancer-affected relatives
^
Last known age (age at diagnosis at any other cancer, age at first polypectomy, age at death or age at last contact, whichever occurred first) for 
colorectal cancer-unaffected relatives.
SD=standard deviation; MMR=mismatch repair
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